ATXS · As filed with the SEC
Astria Therapeutics income statement, by fiscal year
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD, except per-share amounts
| USD, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 77,106,000 | 42,127,000 | 34,264,000 | 15,552,000 |
| General and administrative | 34,452,000 | 25,704,000 | 19,239,000 | 14,807,000 |
| Acquired in-process research and development | — | — | — | 164,617,000 |
| Acquired in-process research and development | — | 15,199,000 | — | — |
| Total operating expenses | 111,558,000 | 83,030,000 | 53,503,000 | 194,976,000 |
| Loss from operations | (111,558,000) | (83,030,000) | (53,503,000) | (194,976,000) |
| Other income (expense): | ||||
| Interest and investment income | 17,360,000 | 10,201,000 | 1,724,000 | 122,000 |
| Other expense, net | (62,000) | (62,000) | (55,000) | (58,000) |
| Total other income, net | 17,298,000 | 10,139,000 | 1,669,000 | 64,000 |
| Net loss | (94,260,000) | (72,891,000) | (51,834,000) | (194,912,000) |
| Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs | — | — | — | (24,437,000) |
| Net loss attributable to common shareholders | — | — | (51,834,000) | (219,349,000) |
| Net loss per share attributable to common shareholders - basic | (1.68) | (2.42) | (3.55) | (24.58) |
| Net loss per share attributable to common shareholders - diluted | (1.68) | (2.42) | (3.55) | (24.58) |
| Weighted-average common shares outstanding used in net loss per share - basic | 56,161,249 | 30,123,316 | 14,620,618 | 8,925,173 |
| Weighted-average common shares outstanding used in net loss per share - diluted | 56,161,249 | 30,123,316 | 14,620,618 | 8,925,173 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.